Understanding reasons and factors for participation and non-participation to a medication adherence program for patients with diabetic kidney disease in Switzerland: a mixed methods study

Carole Bandiera, Liliane Lam, Isabella Locatelli, Jennifer Dotta-Celio, Dina Duarte, Gregoire Wuerzner, Menno Pruijm, Anne Zanchi, Marie P Schneider, Carole Bandiera, Liliane Lam, Isabella Locatelli, Jennifer Dotta-Celio, Dina Duarte, Gregoire Wuerzner, Menno Pruijm, Anne Zanchi, Marie P Schneider

Abstract

Background: An interprofessional medication adherence intervention led by pharmacists, combining motivational interviews and feedback with electronic monitor (EM) drug assessment, was offered to all consecutive patients with diabetic kidney disease (DKD) (estimated glomerular filtration rate < 60 mL/min/1.73 m2) visiting their nephrologist or endocrinologist. Approximately 73% (202/275) of eligible patients declined to participate, and the factors and reasons for refusal were investigated.

Methods: Sociodemographic and clinical data of included patients and those who refused were collected retrospectively for those who had previously signed the general consent form. Multivariate logistic regression analysis was performed to identify independent variables associated with non-participation. Patients who refused or accepted the adherence study were invited to participate in semi-structured interviews. Verbatim transcription, thematic analysis, and inductive coding were performed.

Results: Patients who refused to participate were older (n = 123, mean age 67.7 years, SD:10.4) than those who accepted (n = 57, mean age 64.0 years, SD:10.0, p = 0.027) and the proportion of women was higher among them than among patients who accepted it (30.9% vs 12.3%, p = 0.007). The time from diabetes diagnosis was longer in patients who refused than in those who accepted (median 14.2 years IQR 6.9-22.7 vs. 8.6 years, IQR 4.5-15.9, p = 0.003). Factors associated with an increased risk of non-participation were female sex (OR 3.8, 95% CI 1.4-10.0, p = 0.007) and the time from diabetes diagnosis (OR 1.05, 95% CI 1.01-1.09, p = 0.019). The included patients who were interviewed (n = 14) found the interprofessional intervention useful to improve their medication management, support medication literacy, and motivation. Patients who refused to participate and who were interviewed (n = 16) explained no perceived need, did not agree to use EM, and perceived the study as a burden and shared that the study would have been beneficial if introduced earlier in their therapeutic journey. Other barriers emerged as difficult relationships with healthcare providers, lack of awareness of the pharmacist's role, and negative perception of clinical research.

Conclusions: Investigating the factors and reasons for participation and non-participation in a study helps tailor intervention designs to the needs of polypharmacy patients. Patients who refused the adherence intervention may not be aware of the benefits of medication management and medication literacy. There is an urgent need to advocate for interprofessional outpatient collaborations to support medication adherence in patients with DKD. Trial registration Clinicaltrials.gov NCT04190251_PANDIA IRIS.

Keywords: Chronic renal insufficiency; Diabetes mellitus; Diabetic nephropathies; Electronic adherence monitoring; Interprofessional program; Interventions; Medication adherence; Patient preference; Patient satisfaction; Patient selection; Pharmacists; Qualitative research.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2022. The Author(s).

Figures

Fig. 1
Fig. 1
Design of the PART-PANDIA study

References

    1. International-Diabetes-Federation. Diabetes now affects one in 10 adults worldwide 2021 . Accessed 22 Nov 2021.
    1. Kaiser A, Vollenweider P, Waeber G, Marques-Vidal P. Prevalence, awareness and treatment of type 2 diabetes mellitus in Switzerland: the CoLaus study. Diabet Med. 2012;29(2):190–197.
    1. Diabetesuisse. A propos du diabète 2022 . Accessed 28 June 2022.
    1. Stamm C, Zanchi A, Burnier M. Diabète et insuffisance rénale terminale. Evolution en huit ans dans le canton de Vaud. Rev Méd Suisse. 2011;284:495.
    1. Helou N, Dwyer A, Shaha M, Zanchi A. Multidisciplinary management of diabetic kidney disease: a systematic review and meta-analysis. JBI Database System Rev Implement Rep. 2016;14(7):169–207.
    1. Sabate E. Adherence to long-term therapies: evidence for action. Geneva: World Health Organization (WHO); 2003.
    1. Kardas P, Lewek P, Matyjaszczyk M. Determinants of patient adherence: a review of systematic reviews. Front Pharmacol. 2013;4:91.
    1. Roy L, White-Guay B, Dorais M, Dragomir A, Lessard M, Perreault S. Adherence to antihypertensive agents improves risk reduction of end-stage renal disease. Kidney Int. 2013;84(3):570–577.
    1. Balasubramaniam S, Lim SL, Goh LH, Subramaniam S, Tangiisuran B. Evaluation of illness perceptions and their associations with glycaemic control, medication adherence and chronic kidney disease in type 2 diabetes mellitus patients in Malaysia. Diabetes Metab Syndr. 2019;13(4):2585–2591.
    1. Egede LE, Gebregziabher M, Dismuke CE, Lynch CP, Axon RN, Zhao Y, et al. Medication nonadherence in diabetes: longitudinal effects on costs and potential cost savings from improvement. Diabetes Care. 2012;35(12):2533–2539.
    1. Lelubre M, Kamal S, Genre N, Celio J, Gorgerat S, Hugentobler Hampai D, et al. Interdisciplinary medication adherence program: the example of a University community pharmacy in Switzerland. Biomed Res Int. 2015;2015:103546.
    1. Bandiera C, Dotta-Celio J, Locatelli I, Nobre D, Wuerzner G, Pruijm M, et al. Interprofessional Medication Adherence Program for Patients With Diabetic Kidney Disease: Protocol for a Randomized Controlled and Qualitative Study (PANDIA-IRIS) JMIR Res Protoc. 2021;10(3):e25966.
    1. Robiner WN, Yozwiak JA, Bearman DL, Strand TD, Strasburg KR. Barriers to clinical research participation in a diabetes randomized clinical trial. Soc Sci Med. 2009;68(6):1069–1074.
    1. Mc Sharry J, Dinneen SF, Humphreys M, O'Donnell M, O'Hara MC, Smith SM, et al. Barriers and facilitators to attendance at Type 2 diabetes structured education programmes: a qualitative study of educators and attendees. Diabet Med. 2019;36(1):70–79.
    1. Thoolen B, de Ridder D, Bensing J, Gorter K, Rutten G. Who participates in diabetes self-management interventions?: Issues of recruitment and retainment. Diabetes Educ. 2007;33(3):465–474.
    1. Allory E, Lucas H, Maury A, Garlantezec R, Kendir C, Chapron A, et al. Perspectives of deprived patients on diabetes self-management programmes delivered by the local primary care team: a qualitative study on facilitators and barriers for participation, in France. BMC Health Serv Res. 2020;20(1):855.
    1. Horigan G, Davies M, Findlay-White F, Chaney D, Coates V. Reasons why patients referred to diabetes education programmes choose not to attend: a systematic review. Diabet Med. 2017;34(1):14–26.
    1. Fisher JD, Fisher WA, Amico KR, Harman JJ. An information-motivation-behavioral skills model of adherence to antiretroviral therapy. Health Psychol. 2006;25(4):462–473.
    1. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet. 2007;370(9596):1453–1457.
    1. Sheen YJ, Sheu WH. Risks of rapid decline renal function in patients with type 2 diabetes. World J Diabetes. 2014;5(6):835–846.
    1. KDIGO. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. 2013.
    1. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF, 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604–612.
    1. Kammer M, Heinzel A, Willency JA, Duffin KL, Mayer G, Simons K, et al. Integrative analysis of prognostic biomarkers derived from multiomics panels helps discrimination of chronic kidney disease trajectories in people with type 2 diabetes. Kidney Int. 2019;96(6):1381–1388.
    1. Krolewski AS. Progressive renal decline: the new paradigm of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2015;38(6):954–962.
    1. StataCorp. Stata Statistical Software: Release 17. College Station, TX: StataCorp LLC; 2021.
    1. Braun V, Clarke V. Using thematic analysis in psychology. Qual Res Psychol. 2006;3(2):77–101.
    1. O'Brien BC, Harris IB, Beckman TJ, Reed DA, Cook DA. Standards for reporting qualitative research: a synthesis of recommendations. Acad Med. 2014;89(9):1245–1251.
    1. Lamine F, Lalubin F, Pitteloud N, Burnier M, Zanchi A. Chronic kidney disease in type 2 diabetic patients followed-up by primary care physicians in Switzerland: prevalence and prescription of antidiabetic drugs. Swiss Med Wkly. 2016;146:w14282.
    1. de Vries ST, Keers JC, Visser R, de Zeeuw D, Haaijer-Ruskamp FM, Voorham J, et al. Medication beliefs, treatment complexity, and non-adherence to different drug classes in patients with type 2 diabetes. J Psychosom Res. 2014;76(2):134–138.
    1. Foot H, La Caze A, Gujral G, Cottrell N. The necessity-concerns framework predicts adherence to medication in multiple illness conditions: a meta-analysis. Patient Educ Couns. 2016;99(5):706–717.
    1. Shahin W, Kennedy GA, Stupans I. The Consequences of general medication beliefs measured by the beliefs about medicine questionnaire on medication adherence: a systematic review. Pharmacy (Basel). 2020;8(3):147.
    1. Sieben A, Bredie SJH, Luijten J, van Laarhoven C, van Dulmen S, van Onzenoort HAW. Prior medication adherence of participants and non participants of a randomized controlled trial to improve patient adherence in cardiovascular risk management. BMC Med Res Methodol. 2019;19(1):95.
    1. Caputo J, Pavalko EK, Hardy MA. The long-term effects of caregiving on women's health and mortality. J Marriage Fam. 2016;78(5):1382–1398.
    1. Polenick CA, Stanz SD, Leggett AN, Maust DT, Hodgson NA, Kales HC. Stressors and resources related to medication management: associations with spousal caregivers' role overload. Gerontologist. 2020;60(1):165–173.
    1. Abegaz TM, Shehab A, Gebreyohannes EA, Bhagavathula AS, Elnour AA. Nonadherence to antihypertensive drugs: a systematic review and meta-analysis. Medicine. 2017;96(4):e5641.
    1. Vervloet M, Korevaar JC, Leemrijse CJ, Paget J, Zullig LL, van Dijk L. Interventions to improve adherence to cardiovascular medication: what about gender differences? a systematic literature review. Patient Prefer Adherence. 2020;14:2055–2070.
    1. Gurgoze MT, van der Galien OP, Limpens MAM, Roest S, Hoekstra RC, IJjpma AS, et al. Impact of sex differences in co-morbidities and medication adherence on outcome in 25 776 heart failure patients. ESC Heart Fail. 2020 doi: 10.1002/ehf2.13113.
    1. Lewey J, Shrank WH, Bowry AD, Kilabuk E, Brennan TA, Choudhry NK. Gender and racial disparities in adherence to statin therapy: a meta-analysis. Am Heart J. 2013;165(5):665–78.
    1. Boucquemont J, Pai ALH, Dharnidharka VR, Hebert D, Furth SL, Foster BJ. Gender differences in medication adherence among adolescent and young adult kidney transplant recipients. Transplantation. 2019;103(4):798–806.
    1. Scheurer D, Choudhry N, Swanton KA, Matlin O, Shrank W. Association between different types of social support and medication adherence. Am J Manag Care. 2012;18(12):e461–e467.
    1. Chrvala CA, Sherr D, Lipman RD. Diabetes self-management education for adults with type 2 diabetes mellitus: a systematic review of the effect on glycemic control. Patient Educ Couns. 2016;99(6):926–943.
    1. Steinsbekk A, Rygg LO, Lisulo M, Rise MB, Fretheim A. Group based diabetes self-management education compared to routine treatment for people with type 2 diabetes mellitus. A systematic review with meta-analysis. BMC Health Serv Res. 2012;12:213.
    1. Houghton C, Dowling M, Meskell P, Hunter A, Gardner H, Conway A, et al. Factors that impact on recruitment to randomised trials in health care: a qualitative evidence synthesis. Cochrane Database Syst Rev. 2020;10:45.
    1. Flink M, Brandberg C, Ekstedt M. Why patients decline participation in an intervention to reduce re-hospitalization through patient activation: whom are we missing? Trials. 2019;20(1):82.
    1. Conn VS, Ruppar TM. Medication adherence outcomes of 771 intervention trials: systematic review and meta-analysis. Prev Med. 2017;99:269–276.
    1. Hildebrand JA, Billimek J, Olshansky EF, Sorkin DH, Lee JA, Evangelista LS. Facilitators and barriers to research participation: perspectives of Latinos with type 2 diabetes. Eur J Cardiovasc Nurs. 2018;17(8):737–741.
    1. Rosca A, Krones T, Biller-Andorno N. Shared decision making: patients have a right to be informed about possible treatment options and their risks and benefits. Swiss Med Wkly. 2020;150:w20268.

Source: PubMed

Подписаться